MannKind — Third Quarter 2026 Earnings Summary

MannKind Corporation reported third-quarter 2026 total revenues of $101.9 million, representing a 24% increase compared to the same period in 2025. Commercial product revenue reached $45.0 million, driven by the rapid adoption of the newly approved Furoscix ReadyFlow, which accounted for approximately 75% of weekly shipments, alongside an 80% increase in new-to-brand Afrezza pediatric prescriptions. The company advanced its nintedanib DPI program into a global Phase 2 trial following positive Phase 1b results and entered a collaboration with Rose Pharma for an inhaled GLP-1 weight management program. Despite the revenue growth, the company reported a net loss of $23.2 million for the quarter, primarily due to increased selling, general, and administrative expenses associated with commercial launches and the acquisition of scPharma.